Otros idiomas HUTCHMED (China) Limited Nasdaq

Acciones

HCM

US44842L1035

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 31/05/2024			Varia. Cinco días.	Varia. 1 de enero.
18,53 ^USD	-1,70 %		-1,07 %	+2,32 %

24/05	HUTCHMED (China) Limited destaca las presentaciones de datos nuevos y actualizados de varios estudios de compuestos descubiertos por HUTCHMED en la próxima Sociedad Americana de Oncología Clínica	CI
20/05	Dimite el presidente de Hutchmed (China) y se nombra a su sucesor	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

HUTCHMED Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology	24/05
Hutchmed (China) Chairman Resigns, Successor Named	20/05
Hutchmed China Simon To leaves role, succeeded by Dan Eldar	17/05
Hutchmed Announces Retirement of Simon To as Chairman, Names Dan Eldar Successor	17/05
HUTCHMED Limited Announces Executive Changes	17/05
Hutchmed (China) to Present Sovleplenib Phase III Data at EHA2024 Congress	17/05
HUTCHMED Limited Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to Be Presented at the Upcoming EHA2024 Congress	17/05
Transcript : HUTCHMED Limited Presents at Bank of America Health Care Conference 2024, May-15-2024 02:20 PM	15/05
Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies	14/05
Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer	14/05
HUTCHMED Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China	14/05
Hutchmed Starts Phase 2/3 Trials for Pancreatic Cancer Drug in China; Shares Rise 3%	14/05
Hutchmed Begins Phase 3 Trials for Leukemia Medication in China	14/05
HUTCHMED Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui	14/05
HUTCHMED Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024	08/05
Hutchmed notes CHMP's positive opinion for fruiquintinib approval	26/04
European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer	26/04
Hutchmed to Present New Data at US Cancer Research Conference	05/04
HUTCHMED Limited Highlights Data to be Presented at AACR Congress 2024	05/04
Hutchmed endometrial cancer treatment application accepted for review	02/04

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas HUTCHMED (China) Limited Nasdaq

Acciones

HCM

US44842L1035

Otros idiomas

Filtros